![Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine](https://mma.prnewswire.com/media/792569/Slide1.jpg?p=facebook)
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
![Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer | Business Wire Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer | Business Wire](https://mms.businesswire.com/media/20210413005428/en/870962/5/3350.jpg)
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer | Business Wire
![Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS - Clinical Trial Recruitment Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS - Clinical Trial Recruitment](https://mms.businesswire.com/media/20200114005254/en/767166/4/480_Alexion_CHAMPION-ALS_Trial_visual_10Jan2020.jpg)
Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS - Clinical Trial Recruitment
![Merck announces positive results from pivotal phase 3 STELLAR trial evaluating the treatment of Pulmonary Arterial Hypertension (PAH) - The Indian Practitioner Merck announces positive results from pivotal phase 3 STELLAR trial evaluating the treatment of Pulmonary Arterial Hypertension (PAH) - The Indian Practitioner](https://theindianpractitioner.com/wp-content/uploads/2022/10/Merck-announces-positive-results-from-pivotal-phase-3-STELLAR-trial-evaluating-the-treatment-of-Pulmonary-Arterial-Hypertension-PAH.jpg)
Merck announces positive results from pivotal phase 3 STELLAR trial evaluating the treatment of Pulmonary Arterial Hypertension (PAH) - The Indian Practitioner
![Cardiotoxicity of CPX-351 vs 7+3 in Previously Untreated High-Risk or Secondary AML: Post Hoc Analysis of a Pivotal Phase III Trial | CCO Cardiotoxicity of CPX-351 vs 7+3 in Previously Untreated High-Risk or Secondary AML: Post Hoc Analysis of a Pivotal Phase III Trial | CCO](https://d8tzmbmuvomgp.cloudfront.net/medialibrary/00010/D92F6D97-C11C-4D1B-AA66-A537A3493A19.png)
Cardiotoxicity of CPX-351 vs 7+3 in Previously Untreated High-Risk or Secondary AML: Post Hoc Analysis of a Pivotal Phase III Trial | CCO
![Study design, including the phase 3 pivotal trials (AD-301, AD-302) and... | Download Scientific Diagram Study design, including the phase 3 pivotal trials (AD-301, AD-302) and... | Download Scientific Diagram](https://www.researchgate.net/publication/319189550/figure/fig2/AS:866923180982273@1583702001406/Study-design-including-the-phase-3-pivotal-trials-AD-301-AD-302-and-the-extension.png)
Study design, including the phase 3 pivotal trials (AD-301, AD-302) and... | Download Scientific Diagram
![Marinus on X: "We're excited to share @TheLancetNeuro has published pivotal Phase 3 results for our investigational medicine for the treatment of seizures associated with #CDKL5 deficiency disorder (CDD). https://t.co/8b93oUPlbJ https://t.co/Mqk5DUZVKx" / Marinus on X: "We're excited to share @TheLancetNeuro has published pivotal Phase 3 results for our investigational medicine for the treatment of seizures associated with #CDKL5 deficiency disorder (CDD). https://t.co/8b93oUPlbJ https://t.co/Mqk5DUZVKx" /](https://pbs.twimg.com/media/FQTMjQhX0AAsiit.jpg)
Marinus on X: "We're excited to share @TheLancetNeuro has published pivotal Phase 3 results for our investigational medicine for the treatment of seizures associated with #CDKL5 deficiency disorder (CDD). https://t.co/8b93oUPlbJ https://t.co/Mqk5DUZVKx" /
![Novaliq and Bosch+Laumb Unveil Pivotal Phase 3 Data for Revolutionary Dry Eye Treatment NOVO3 : u/MarknTeladvisors Novaliq and Bosch+Laumb Unveil Pivotal Phase 3 Data for Revolutionary Dry Eye Treatment NOVO3 : u/MarknTeladvisors](https://preview.redd.it/novaliq-and-bosch-laumb-unveil-pivotal-phase-3-data-for-v0-kqsvtf8asy9c1.png?width=1920&format=png&auto=webp&s=041d466ff4133823a49485b3a013ceb787b78148)
Novaliq and Bosch+Laumb Unveil Pivotal Phase 3 Data for Revolutionary Dry Eye Treatment NOVO3 : u/MarknTeladvisors
![Actinium Pharma on X: "Actinium's Pivotal Phase 3 SIERRA trial fully enrolled. Data update in 4Q 2021 with topline data expected in mid-2022. Iomab-B showing clear value proposition through 75% enrollment. Learn Actinium Pharma on X: "Actinium's Pivotal Phase 3 SIERRA trial fully enrolled. Data update in 4Q 2021 with topline data expected in mid-2022. Iomab-B showing clear value proposition through 75% enrollment. Learn](https://pbs.twimg.com/media/FBlpEIWWQAcuE6C.jpg)
Actinium Pharma on X: "Actinium's Pivotal Phase 3 SIERRA trial fully enrolled. Data update in 4Q 2021 with topline data expected in mid-2022. Iomab-B showing clear value proposition through 75% enrollment. Learn
![News - @RevivaPharma $RVPH Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia : u/DD_SUPPORT_ News - @RevivaPharma $RVPH Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia : u/DD_SUPPORT_](https://preview.redd.it/rvph-last-patient-evaluated-in-pivotal-phase-3-recover-v0-mi4c9u17csqb1.jpg?width=1200&format=pjpg&auto=webp&s=9aec1d66448cd1d7cc799bf41e2cef0585cc2c28)
News - @RevivaPharma $RVPH Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia : u/DD_SUPPORT_
![Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy | Cytokinetics, Inc. Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy | Cytokinetics, Inc.](https://ir.cytokinetics.com/sites/g/files/knoqqb83726/themes/site/client_site/dist/images/bg-investors-hero-gray.jpg)
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy | Cytokinetics, Inc.
![Bristol Myers Squibb - Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast) Bristol Myers Squibb - Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)](https://mms.businesswire.com/media/20210423005134/en/873564/4/BMS-Deucra-Anchor.jpg)